In selected patients with colorectal and neuroendocrine liver metastases, the outcome of liver resection is well established with 5-year survival rates ranging from 25% to 60%. However, the role of liver resection for non-colorectal non-neuroendocrine (NCRCE) liver metastases has not been fully established. Liver metastases in breast cancer are common and a small number of those patients may be suitable for surgical resection. There have been some case series with low mortality and morbidity and prolonged survival after liver resection. We performed this review to evaluate the overall and disease free survival after liver resections for breast metastases. Extensive search of Pubmed, Medline, Cochrane database was performed and data was anal...
Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: F...
Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: F...
none10noBackground: The role of liver resection for metastatic breast carcinoma is still debated. Me...
AbstractIn selected patients with colorectal and neuroendocrine liver metastases, the outcome of liv...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
AIMS: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Contains fulltext : 109372pub.pdf (publisher's version ) (Closed access)AIMS: Pati...
Introduction: Breast cancer is the most incident cancer in the world, accounting for 25% of new canc...
Copyright © 2014 Malte Weinrich et al.This is an open access article distributed under the Creative ...
The role of liver resection for non-colorectal, non-neuroendocrine, non-sarcoma (NCNNNS) metastases ...
The role of liver resection for non-colorectal, non-neuroendocrine, non-sarcoma (NCNNNS) metastases ...
In patients with breast cancer (BC) the liver is one of the site of distant metastases, accounting f...
Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: F...
Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: F...
none10noBackground: The role of liver resection for metastatic breast carcinoma is still debated. Me...
AbstractIn selected patients with colorectal and neuroendocrine liver metastases, the outcome of liv...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
AIMS: Patients with breast cancer metastasized to the liver have a median survival of 4-33 months an...
Contains fulltext : 109372pub.pdf (publisher's version ) (Closed access)AIMS: Pati...
Introduction: Breast cancer is the most incident cancer in the world, accounting for 25% of new canc...
Copyright © 2014 Malte Weinrich et al.This is an open access article distributed under the Creative ...
The role of liver resection for non-colorectal, non-neuroendocrine, non-sarcoma (NCNNNS) metastases ...
The role of liver resection for non-colorectal, non-neuroendocrine, non-sarcoma (NCNNNS) metastases ...
In patients with breast cancer (BC) the liver is one of the site of distant metastases, accounting f...
Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: F...
Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: F...
none10noBackground: The role of liver resection for metastatic breast carcinoma is still debated. Me...